162 related articles for article (PubMed ID: 10597780)
1. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.
Pernerstorfer-Schoen H; Schindler K; Parschalk B; Schindl A; Thoeny-Lampert S; Wunderer K; Elmadfa I; Tschachler E; Jilma B
AIDS; 1999 Dec; 13(17):2389-96. PubMed ID: 10597780
[TBL] [Abstract][Full Text] [Related]
2. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy.
Shevitz AH; Knox TA; Spiegelman D; Roubenoff R; Gorbach SL; Skolnik PR
AIDS; 1999 Jul; 13(11):1351-7. PubMed ID: 10449288
[TBL] [Abstract][Full Text] [Related]
3. Positive impact of protease inhibitors on body composition and energy expenditure in HIV-infected and AIDS patients.
Schindler K; Pernerstorfer-Schoen H; Schneider B; Rieger A; Elmadfa I
Ann N Y Acad Sci; 2000 May; 904():603-6. PubMed ID: 10865811
[No Abstract] [Full Text] [Related]
4. Effects of HIV and antiretroviral therapy on resting energy expenditure in adult HIV-infected women-a matched, prospective, cross-sectional study.
Mittelsteadt AL; Hileman CO; Harris SR; Payne KM; Gripshover BM; McComsey GA
J Acad Nutr Diet; 2013 Aug; 113(8):1037-43. PubMed ID: 23601434
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection.
Hardin DS; Ellis KJ; Rice J; Doyle ME
J Pediatr Endocrinol Metab; 2004 Mar; 17(3):321-5. PubMed ID: 15112908
[TBL] [Abstract][Full Text] [Related]
6. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
7. Determinants of increased energy expenditure in HIV-infected women.
Grinspoon S; Corcoran C; Miller K; Wang E; Hubbard J; Schoenfeld D; Anderson E; Basgoz N; Klibanski A
Am J Clin Nutr; 1998 Sep; 68(3):720-5. PubMed ID: 9734753
[TBL] [Abstract][Full Text] [Related]
8. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
9. Calculating energy requirements for men with HIV/AIDS in the era of highly active antiretroviral therapy.
Batterham MJ; Morgan-Jones J; Greenop P; Garsia R; Gold J; Caterson I
Eur J Clin Nutr; 2003 Feb; 57(2):209-17. PubMed ID: 12571651
[TBL] [Abstract][Full Text] [Related]
10. The effect of protease inhibitors on weight and body composition in HIV-infected patients.
Silva M; Skolnik PR; Gorbach SL; Spiegelman D; Wilson IB; Fernández-DiFranco MG; Knox TA
AIDS; 1998 Sep; 12(13):1645-51. PubMed ID: 9764784
[TBL] [Abstract][Full Text] [Related]
11. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
12. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
13. Effect of indinavir on HIV-related wasting.
Carbonnel F; Maslo C; Beaugerie L; Carrat F; Wirbel E; Aussel C; Gobert JG; Girard PM; Gendre JP; Cosnes J; Rozenbaum W
AIDS; 1998 Oct; 12(14):1777-84. PubMed ID: 9792378
[TBL] [Abstract][Full Text] [Related]
14. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
15. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.
Miller TL; Mawn BE; Orav EJ; Wilk D; Weinberg GA; Nicchitta J; Furuta L; Cutroni R; McIntosh K; Burchett SK; Gorbach SL
Pediatrics; 2001 May; 107(5):E77. PubMed ID: 11331727
[TBL] [Abstract][Full Text] [Related]
16. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.
Hadigan C; Corcoran C; Stanley T; Piecuch S; Klibanski A; Grinspoon S
J Clin Endocrinol Metab; 2000 Jan; 85(1):35-41. PubMed ID: 10634360
[TBL] [Abstract][Full Text] [Related]
17. Resting energy expenditure, weight loss, and altered body composition in HIV infection.
Schwenk A; Höffer-Belitz E; Jung B; Kremer G; Bürger B; Salzberger B; Diehl V; Schrappe M
Nutrition; 1996 Sep; 12(9):595-601. PubMed ID: 8878168
[TBL] [Abstract][Full Text] [Related]
18. Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis.
Batterham MJ
Am J Clin Nutr; 2005 Mar; 81(3):702-13. PubMed ID: 15755842
[TBL] [Abstract][Full Text] [Related]
19. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
[TBL] [Abstract][Full Text] [Related]
20. Protease inhibitor therapy in HIV-infected children.
Feingold AR; Rutstein RM; Meislich D; Brown T; Rudy BJ
AIDS Patient Care STDS; 2000 Nov; 14(11):589-93. PubMed ID: 11155900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
